A vasculopatia livedoide é um distúrbio dos vasos sanguíneos que causa úlceras dolorosas e cicatrizes (atrofia branca) nos pés e na parte inferior das pernas. Esses sintomas podem persistir por meses a anos e as úlceras freqüentemente recorrem. As lesões da vasculopatia livedoide aparecem como marcas e manchas vermelhas ou roxas dolorosas que podem progredir para úlceras pequenas, sensíveis e irregulares. Os sintomas tendem a piorar nos meses de inverno e verão e afetam mais as mulheres do que os homens. A vasculopatia livedoide pode ocorrer isoladamente ou em combinação com outra doença, como lúpus ou trombofilia.
Introdução
O que você precisa saber de cara
A vasculopatia livedoide é um distúrbio dos vasos sanguíneos que causa úlceras dolorosas e cicatrizes (atrofia branca) nos pés e na parte inferior das pernas. Esses sintomas podem persistir por meses a anos e as úlceras freqüentemente recorrem. As lesões da vasculopatia livedoide aparecem como marcas e manchas vermelhas ou roxas dolorosas que podem progredir para úlceras pequenas, sensíveis e irregulares. Os sintomas tendem a piorar nos meses de inverno e verão e afetam mais as mulheres do que os homens. A vasculopatia livedoide pode ocorrer isoladamente ou em combinação com outra doença, como lúpus ou trombofilia.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 29 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 50 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Vasculopatia livedoide
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Pesquisa e ensaios clínicos
Nenhum ensaio clínico registrado para esta condição.
Publicações mais relevantes
Treatment outcomes in patients of livedoid vasculopathy following antithrombotic therapy: A retrospective observational study.
Background Livedoid vasculopathy, characterised by painful ulcers and atrophie blanche, significantly affects the quality of life of patients. Data pertaining to the efficacy of various available treatment options for this condition is limited, especially in India. Aim The study aimed to evaluate the treatment outcomes, clinicodemographic features, and associated laboratory abnormalities in patients with livedoid vasculopathy at a tertiary care centre. Methods This retrospective observational study analysed the case records and clinical photos of all clinically and histologically proven cases of livedoid vasculopathy who received antithrombotic treatment and were followed up for a minimum of 6 months. The primary endpoint was the proportion of patients who achieved a pain visual analogue (VAS) score of zero and complete healing of livedoid vasculopathy ulcers at 3 months. The secondary endpoint was the proportion of patients who achieved a pain VAS score of zero and complete healing of livedoid vasculopathy ulcers at 6 months. Side-effects, improvements in the dermatological life quality index (DLQI), clinicodemographic features, and associated laboratory abnormalities were also analysed. Results Of the 26 patients who satisfied the inclusion and exclusion criteria, 20 were males. At 3 months, 65.3% (17) of patients achieved the primary endpoint. Of these, 11 had received rivaroxaban (10mg) once daily and six had received aspirin (150mg) once daily. At 6 months, 96.1% (25) of patients had complete ulcer healing and achieved a VAS pain score of 0. Of these, 11 patients had received rivaroxaban, eight had received a combination of rivaroxaban and aspirin, and six had received aspirin. The improvements in VAS and DLQI at 3 months and 6 months were significant. None of the patients had any adverse effects from the therapy. Limitations The small sample size and its retrospective nature were limitations of the study. Conclusion Monotherapy with rivaroxaban or aspirin can effectively heal the ulcers, successfully achieve pain control, and improve the quality of life in livedoid vasculopathy. However, a fraction of patients may need a combination of the two to achieve these therapeutic goals. Both monotherapy and combination therapy are safe and not associated with significant side effects.
Treatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series.
Livedoid vasculopathy (LV) is a rare chronic recurrent occlusive disease characterized by painful ulcers and atrophic porcelain-white scars. Owing to the lack of strict treatment guidelines, the commonly used traditional treatment methods are not effective in some patients. Therefore, there is an urgent need to develop new therapies for LV. Here we report 4 cases of LV that were successfully treated with the Janus kinase (JAK) inhibitors. The present study revealed a significant improvement in clinical activity and pain relief in patients with LV after the administration of abrocitinib (3 patients) or upadacitinib (1 patient). The median composite clinical score derived from erythema, ulceration, and physician-assessed pain fell from 7.25 ± 0.25 at baseline to 4.50 ± 0.50 at 4 weeks, 2.50 ± 0.50 at 8 weeks, and 1.00 ± 0.707 at 12 weeks. The remission time ranged from 5 to 8 weeks, with a mean remission time of 6.75 ± 1.258 weeks. Two patients experienced disease recurrence after the discontinuation of JAK inhibitor therapy. The average relapse time was 13.00 ± 7.071 months after drug withdrawal. The mean follow-up period was 6.00 ± 1.414 months. During the long follow-up period, only 1 patient showed a slight increase in the total cholesterol level, and no other adverse reactions were observed. Our study included 1 pediatric patient treated with upadacitinib. No adverse reactions occurred in this pediatric patient. We believe that JAK inhibitors could be a promising therapeutic option for LV.
Livedoid Vasculopathy: Analysis of Hematological Parameters and Response to Rivaroxaban.
Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with poorly understood pathogenesis, potentially involving hypercoagulability and inflammation. The aim of this study included analyzing the association between these indices and disease severity, as well as evaluating the real-world efficacy of rivaroxaban, to determine optimal personalized treatment strategies for LV. This retrospective analysis was conducted on 41 patients with LV and 19 healthy controls. Patients were treated with 10 mg daily rivaroxaban and assessed using the Livedoid Vasculopathy Activity/Severity Score and the Numerical Rating Scale. Thirty-two females (78.0%) were included, with a mean age of 26.1 years. The platelet count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR) and plateletcrit levels were significantly increased in patients with LV compared with those in healthy controls. Platelet count, plateletcrit and PLR positively showed a positive correlation with clinical severity scores, which can serve as simple and cost-effective measures for assessing disease severity. Rivaroxaban at 10 mg daily resulted in disease control in 78.0% of patients within 3 weeks. Patients with inadequate responses exhibited higher severity scores and required dose adjustments or combination therapy. Adverse effects were generally mild, comprising 6 instances of menorrhagia, 2 cases of bleeding hematochezia and 1 allergic reaction.
Treatment of livedoid vasculopathy with sulodexide: A prospective study of 35 cases.
Livedoid vasculopathy (LV) is a vascular occlusive disease, lacking a standardized treatment strategy. Sulodexide as a heparin-like agent has demonstrated favorable efficacy and safety profiles in certain thrombotic disorders. This study is designed to evaluate the efficacy and safety of sulodexide in the treatment of LV. In this single-center prospective study, 35 patients diagnosed with LV were treated with sulodexide. Efficacy outcomes were assessed at standardized intervals: baseline and at weeks 1, 4, 8, 12 following treatment initiation. A total of 35 patients receiving sulodexide therapy were enrolled in the study. Thirty-one patients (88.6%) achieved complete clinical resolution with sulodexide monotherapy. Two patients (5.7%) withdrew due to suboptimal therapeutic response, while two others (5.7%) required adjunctive baricitinib. Eight (22.9%) mild adverse events related to sulodexide were reported. No moderate-severe adverse events occurred. Our study demonstrates that sulodexide monotherapy is a clinically effective and well-tolerated therapeutic option for patients with LV. Adjunctive JAK inhibitor therapy, when clinically indicated, may yield superior therapeutic outcomes.
JAK inhibitors in livedoid vasculopathy associated with thrombophilia and refractory to anticoagulation: report and literature review.
Publicações recentes
Refractory Livedoid Vasculopathy Successfully Treated with CHAP Therapy and Punch Grafts: Two Case Reports.
Assessment of the use of biologic drugs in the treatment of primary antiphospholipid syndrome.
JAK inhibitors in livedoid vasculopathy associated with thrombophilia and refractory to anticoagulation: report and literature review.
Treatment outcomes in patients of livedoid vasculopathy following antithrombotic therapy: A retrospective observational study.
Differential response to Janus kinase inhibitors in refractory livedoid vasculopathy: Biomarker-guided therapy may improve clinical response.
📚 EuropePMC241 artigos no totalmostrando 180
JAK inhibitors in livedoid vasculopathy associated with thrombophilia and refractory to anticoagulation: report and literature review.
Anais brasileiros de dermatologiaTreatment outcomes in patients of livedoid vasculopathy following antithrombotic therapy: A retrospective observational study.
Indian journal of dermatology, venereology and leprologyDifferential response to Janus kinase inhibitors in refractory livedoid vasculopathy: Biomarker-guided therapy may improve clinical response.
JAAD internationalT-cell-predominant inflammation in livedoid vasculopathy and response to baricitinib.
JAAD internationalTreatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series.
Case reports in dermatologyLivedoid Vasculopathy: Analysis of Hematological Parameters and Response to Rivaroxaban.
Journal of cutaneous medicine and surgeryTreatment of livedoid vasculopathy with sulodexide: A prospective study of 35 cases.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGRefractory Livedoid Vasculopathy Successfully Treated with Hyperbaric Oxygen Therapy and Tofacitinib.
Indian dermatology online journalAutologous Platelet-Derived Therapies in Chronic Leg Ulcers: Platelet-Rich Fibrin in Venous Ulcer and Growth Factor Concentrate in Livedoid Vasculopathy.
International journal of dermatologyRefractory livedoid vasculopathy successfully treated with immunosuppressive therapy.
JAAD case reportsDevelopment of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.
Current rheumatology reportsLong-Term Efficacy of Guideline-Followed Treatment in Patients with Livedoid Vasculopathy: A Single-Center Study.
Advances in wound carePrevalence of Livedoid Vasculopathy Among Patients with Connective Tissue Diseases and Its Association with Thrombophilic Factors: A Hospital-Based Retrospective Cohort (2014-2021).
Clinical, cosmetic and investigational dermatologyUpadacitinib treatment of refractory livedoid vasculopathy: a case report and literature review.
Anais brasileiros de dermatologiaAutoimmune-Associated Livedoid Vasculopathy: Response to Immunomodulatory Therapy.
CureusSuccessful Treatment of Refractory Livedoid Vasculopathy with Upadacitinib: A Case Report.
Clinical, cosmetic and investigational dermatologyClinical Characteristics and Disease Course of Livedoid Vasculopathy: A 10-Year Retrospective Analysis.
Clinical, cosmetic and investigational dermatologySuccessful healing of a chronic ulcer in livedoid vasculopathy using PuraPly: A case report.
JAAD case reportsLong-term efficacy and safety of JAKi in refractory livedoid vasculopathy.
Indian journal of dermatology, venereology and leprologyLivedoid vasculopathy in protein S deficiency.
The Pan African medical journalEffective Treatment of Livedoid Vasculopathy With Oral Tofacitinib.
Clinical case reportsA case report and literature review of livedoid vasculopathy in children.
Frontiers in pediatricsBaricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review.
Journal of inflammation researchLivedoid vasculopathy, calciphylaxis, and Martorell's hypertensive ulcer: update on ischemic ulcers due to impaired microcirculation of the lower limbs.
Anais brasileiros de dermatologiaJanus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review.
The Journal of dermatological treatmentRecurrent painful blisters over the right foot.
JAAD case reportsLivedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers.
Annals of hematologyAddressing Diagnostic Challenges in Livedoid Vasculopathy: A Case Report on Interdisciplinary Management.
CureusClinical and patient reported treatment outcomes of livedoid vasculopathy: a systematic review.
Clinical and experimental dermatology[Translated article] Use of a Spinal Cord Stimulator to Treat Livedoid Vasculopathy: Effective Control of an Untreatable Disease.
Actas dermo-sifiliograficasCo-occurring livedoid vasculopathy and limited cutaneous systemic sclerosis associated gangrene successfully managed with alprostadil and aspirin.
Indian journal of dermatology, venereology and leprologyIdentification of Challenging Diagnostic Factors in Livedoid Vasculopathy: A Retrospective Study.
Clinical, cosmetic and investigational dermatologyNegative Results, Positive Outcome: A Case of Primary Livedoid Vasculopathy With an Elusive Laboratory Workup.
Journal of investigative medicine high impact case reportsAnti-Interleukin 17A Biologic Therapy Attempts on Livedoid Vasculopathy: A Report of Case Series.
Clinical, cosmetic and investigational dermatologyLivedoid Vasculopathy with Severe Debilitating Neuropathy in a Prior Professional Athlete.
CureusThe potential role of tumor necrosis factor-α in thrombosis in livedoid vasculopathy.
Archives of dermatological researchInflammatory and vaso-occlusive ulcers: Part II - Management.
Journal of the American Academy of DermatologyInflammatory and vaso-occlusive ulcers: Part I - Clinical presentation and diagnosis.
Journal of the American Academy of DermatologyRivaroxaban in the treatment of livedoid vasculopathy: A long-term retrospective study.
JAAD internationalUnusual case of retinal arterial branch occlusion: possible variant of Sneddon syndrome.
Archivos de la Sociedad Espanola de OftalmologiaOcclusive cutaneous vasculopathies as cause of chronic ulcers.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGEpidemiology of antiphospholipid syndrome: macro- and microvascular manifestations.
Rheumatology (Oxford, England)Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.
Clinical and experimental dermatology[Compression therapy for inflammatory dermatoses of the legs].
Deutsche medizinische Wochenschrift (1946)Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review.
Clinical, cosmetic and investigational dermatologyAdalimumab in the Treatment of Recalcitrant Livedoid Vasculopathy.
CureusSecondary livedoid vasculopathy following SARS-CoV-2 infection.
Journal of the European Academy of Dermatology and Venereology : JEADVHealing refractory livedoid vasculopathy-related skin ulcers by ozone therapy: a case-based review.
Rheumatology internationalA Refractory Livedoid Vasculopathy Accompanied by Methylene Tetrahydrofolate Reductase Gene Polymorphism Successfully Treated with Hyperbaric Oxygen Therapy.
Annals of dermatologyA case of concomitant clinical and histopathologic features of lymphocytic thrombophilic arteritis and livedoid vasculopathy.
JAAD case reportsLymphocytic vasculitis in livedoid vasculopathy: A report of 137 cases.
Journal of cutaneous pathologyEvaluating complement dysregulation in livedoid vasculopathy using a functional assay.
Blood advancesPunch grafting for the treatment of ulcerated atrophie blanche.
PhlebologyEndothelial dysfunction, thrombophilia, and nailfold capillaroscopic features in livedoid vasculopathy.
Microvascular researchPenile Livedoid Vasculopathy: First Reported Case.
Case reports in vascular medicineDermatological Lesions of Cholesterol Embolisation Syndrome and Kaposi Sarcoma Mimic Primary Systemic Vasculitis: Case report study.
Sultan Qaboos University medical journalRefractory livedoid vasculopathy successfully treated with baricitinib.
International journal of dermatologyThe simultaneous occurrence of livedoid vasculopathy and lymphocytic thrombophilic arteritis in six cases.
The Australasian journal of dermatologyDetection of Bartonella henselae DNA in the blood of patients with livedoid vasculopathy.
Anais brasileiros de dermatologiaPain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.
European journal of case reports in internal medicineCharacteristics of Peripheral Neuropathy in Patients With Livedoid Vasculopathy.
Journal of clinical neuromuscular diseaseA comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
Frontiers in medicine[A particular presentation of a T cell large granular lymphocytic leukaemia].
Annales de pathologieClinical analysis of skin lesions in livedoid vasculopathy: a study of 46 Chinese patients.
International journal of dermatologyBaricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.
Frontiers in immunologyClinical, Laboratory, Histopathological and Therapeutic Profile of Livedoid Vasculopathy: A Case Series of 17 Patients.
Indian dermatology online journalLivedoid vasculopathy and peripheral neuropathy: A retrospective cohort study of 55 Chinese patients and literature review.
International wound journalLivedoid vasculopathy: A review with focus on terminology and pathogenesis.
Vascular medicine (London, England)Vascular Disease Patient Information Page: Livedoid vasculopathy.
Vascular medicine (London, England)Livedoid vasculopathy - A diagnostic and therapeutic challenge.
Frontiers in medicineImmunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry").
LupusBotulinum toxin-A: A novel treatment for livedoid vasculopathy.
JAAD case reportsExcellent Long-term Clinical Response to Rivaroxaban in Livedoid Vasculopathy: A Retrospective Study.
Actas dermo-sifiliograficasComparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
CureusMedium-pressure hyperbaric oxygen therapy for livedoid vasculopathy.
MedicinaA novel combination ("CHAP") regimen for management of livedoid vasculopathy in 12 patients.
Journal of the American Academy of DermatologyEfficacy of adalimumab in the treatment of refractory livedoid vasculopathy: Case report and literature review.
Dermatologic therapyRefractory livedoid vasculopathy in a child successfully treated with baricitinib.
Dermatologic therapyPatients with laboratory criteria of anti-phospholipid syndrome and 'non-criteria' manifestations: a multicenter cohort.
Scandinavian journal of rheumatologyExacerbation of livedoid vasculopathy after coronavirus disease 2019.
European journal of dermatology : EJDLivedoid Vasculopathy Associated With Plasminogen Activator Inhibitor-1 Polymorphisms Treated With Factor Xa Inhibitors.
Actas dermo-sifiliograficasPlatelet count and plateletcrit: Potential haematological biomarkers for livedoid vasculopathy?
The Australasian journal of dermatologyEfficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.
Therapeutic advances in chronic diseaseAdalimumab in Treating Refractory Livedoid Vasculopathy.
VaccinesThe clot thickens with COVID-19 and cryofibrinogenemia: A thought-provoking association.
JAAD case reportsTreatment of Livedoid Vasculopathy With Baricitinib.
JAMA dermatologyPeripheral neuropathy and livedoid vasculopathy.
Journal of neurologyLivedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.
International journal of women's dermatologyPrimary and Secondary Livedoid Vasculopathy: A Report of 2 Cases.
The American Journal of dermatopathologyReal-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy.
Journal of the European Academy of Dermatology and Venereology : JEADVRivaroxaban for treatment of livedoid vasculopathy: A systematic review.
Dermatologic therapyLivedoid Vasculopathy: diagnosis and treatment in pregnant women.
Jornal vascular brasileiroA novel use of intermittent low dose dabigatran for maintenance of remission in livedoid vasculopathy.
Dermatologic therapyA Case of Livedoid Vasculopathy Successfully Treated with Sulodexide.
Annals of dermatologyCutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.
Journal of cutaneous pathologyIntravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.
Journal of cutaneous medicine and surgeryLivedoid vasculopathy and its association with genetic variants: A systematic review.
International wound journalRemission of long-standing livedoid vasculopathy using a whole foods plant-based diet with symptoms recurrent on re-challenge with standard Western diet.
BMJ case reportsRecrudescence of livedoid vasculopathy induced by COVID-19.
International journal of dermatologyLivedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation.
Dermatologic therapyLivedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature.
Dermatologic therapyFrom dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.
Dermatologic therapyRefractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.
Dermatologic therapyClinical and Histopathologic Characteristics of the Main Causes of Vascular Occusion - Part II: Coagulation Disorders, Emboli, and Other.
Actas dermo-sifiliograficasIntravenous Immunoglobulins in a Series of 32 Rare and Recalcitrant Immune Dermatoses.
Acta dermato-venereologicaPlasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.
International wound journal[Diagnosis and treatment of vasculitic ulcerations].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte GebieteDirect immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review.
Clinical and experimental dermatologyPrimary livedoid vasculopathy associated with mononeuritis multiplex.
Dermatology online journalClinical and dermoscopic features of livedoid vasculopathy.
Chinese medical journalLivedoid vasculopathy: A challenging disease to diagnose.
Journal of paediatrics and child healthMethylene tetrahydrofolate reductase C677T polymorphism in Korean livedoid vasculopathy patients.
Journal of the American Academy of DermatologyUnraveling the mystery of Covid-19 cytokine storm: From skin to organ systems.
Dermatologic therapySuccessful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus.
Journal of drugs in dermatology : JDDLivedoid Vasculopathy Associated with Antiphospholipid Antibody Presenting with Leg Ulcer.
Indian journal of pediatricsA 75-year-old woman with primary antiphospholipid syndrome presenting with livedoid vasculopathy.
Dermatologic therapyEfficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.
The Journal of dermatological treatmentIntravenous immunoglobulin in resistant livedoid vasculopathy: Analysis of a case series.
Dermatologic therapyLivedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.
Journal of the European Academy of Dermatology and Venereology : JEADVVasculitic mononeuritis multiplex associated with livedoid vasculopathy.
NeurologiaAtypical Mycobacterial Infection Arising Amid Corticosteroid Therapy for Livedoid Vasculopathy.
Case reports in dermatological medicineUlceration in Prolidase Deficiency: Successful Treatment with Anticoagulants.
Acta dermato-venereologicaIs there a role for hyperbaric oxygen therapy in the treatment of refractory wounds of rare etiology?
Diving and hyperbaric medicineRetiform purpura: Workup and therapeutic considerations in select conditions.
Journal of the American Academy of DermatologyLivedoid vasculopathy: how to diagnose and how to treat?
Journal of the European Academy of Dermatology and Venereology : JEADVLivedoid vasculopathy: does hyperhomocysteinaemia play an aetiological role?
European journal of dermatology : EJDLivedoid vasculopathy presenting with leg ulcers.
Rheumatology (Oxford, England)Retiform non-blanchable purpuric plaques in a patient with systemic lupus erythematosus.
LupusCharacteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Journal of the European Academy of Dermatology and Venereology : JEADVEndovenous Laser Ablation Treatment for Lower Extremity Ulcers Associated With Livedoid Vasculopathy.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]Chronic leg ulcerations associated with livedoid vasculopathy successfully treated with rivaroxaban.
Clinical and experimental dermatologyTopical becaplermin gel is an effective adjuvant for long-standing ulcers of livedoid vasculopathy recalcitrant to anticoagulant therapy.
Clinical and experimental dermatologySystemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin.
Clinical case reportsDermoscopy of early non-ulcerated livedoid vasculopathy.
Acta dermatovenerologica Alpina, Pannonica, et AdriaticaPrevention of recurrent ulceration of livedoid vasculopathy with long-term apixaban monotherapy.
The Journal of dermatologyLivedoid vasculopathy: a compelling diagnosis.
Autopsy & case reportsTraditional Korean medicine treatment for livedoid vasculopathy: Five case reports.
Explore (New York, N.Y.)Systemic therapies for leg ulcers.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGSystemic Lupus Erythematosus Presenting as Livedoid Vasculopathy over the Forearms.
SkinmedUlcerative livedoid vasculopathy responding to clopidogrel.
JAAD case reportsLivedoid Vasculopathy: A French Observational Study Including Therapeutic Options.
Acta dermato-venereologicaThe management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
International journal of dermatologyLivedoid Vasculopathy Presenting in a Patient With Sickle Cell Disease.
The American Journal of dermatopathologyLivedoid vasculopathy in a patient with bullous pemphigoid and primary Sjögren's syndrome.
Reumatologia clinicaTreatment for Livedoid Vasculopathy: A Systematic Review.
JAMA dermatologyTreatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
Actas dermo-sifiliograficasUse of Low-dose Oral Warfarin in Three Cases of Livedoid Vasculopathy.
Indian journal of dermatologyAnalysis of serum levels and cutaneous expression of lipoprotein (a) in 38 patients with livedoid vasculopathy.
Journal of cutaneous pathologyVasculopathies, cutaneous necrosis and emergency in dermatology.
Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografiaThree cases of lymphocytic thrombophilic arteritis presenting with an annular eruption.
The Australasian journal of dermatologyEfficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
BMJ case reportsPrevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.
Journal of the European Academy of Dermatology and Venereology : JEADVTreatment application of rivaroxaban in Chinese patients with livedoid vasculopathy.
Journal of pain researchDermoscopic features of livedoid vasculopathy.
Medicine[Livedoid vasculopathy secondary to coeliac disease].
Annales de dermatologie et de venereologieAnalysis of the German DRG data for livedoid vasculopathy and calciphylaxis.
Journal of the European Academy of Dermatology and Venereology : JEADVFast Cicatrization of Extensive Livedoid Vasculopathy Ulcers under Treatment with Sildenafil.
Annals of dermatologyEnhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions.
Cardiovascular therapeuticsDabigatran in the management of livedoid vasculopathy.
Clinical and experimental dermatology[What's new in clinical dermatology?].
Annales de dermatologie et de venereologieLivedoid vasculopathy - a challenging disease.
Acta reumatologica portuguesaLivedoid vasculopathy and popliteal artery occlusion in a patient with protein S deficiency.
The Journal of dermatologyOcclusive Nonvasculitic Vasculopathy.
The American Journal of dermatopathologyLivedoid vasculopathy: A review of pathogenesis and principles of management.
Indian journal of dermatology, venereology and leprologyRapid remission of severe pain from livedoid vasculopathy by apixaban.
Journal of the European Academy of Dermatology and Venereology : JEADVCoagulation disorders and their cutaneous presentations: Diagnostic work-up and treatment.
Journal of the American Academy of DermatologySuccessful treatment of livedoid vasculopathy with rivaroxaban.
JAAD case reportsTherapeutic effect of autologous platelet-rich plasma (PRP) on recalcitrant cutaneous ulcers in livedoid vasculopathy.
JAAD case reportsRecalcitrant Livedoid Vasculopathy Associated with Hyperhomocysteinaemia Responding to Folic Acid and Vitamins B6/B12 Supplementation.
Acta dermato-venereologicaCase series of recalcitrant livedoid vasculopathy treated with rivaroxaban.
Clinical and experimental dermatologyAnticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
The Lancet. HaematologyNew hope for patients with livedoid vasculopathy.
The Lancet. HaematologyLivedoid Vasculopathy Associated with HIV Infection in Two Patients: A Causal Relationship?
Acta dermato-venereologicaLivedoid Vasculopathy with Hyperhomocysteinemia Responding to Hyperbaric Oxygen Therapy.
Indian journal of dermatologyCilostazol: A novel agent in recalcitrant livedoid vasculopathy.
Indian journal of dermatology, venereology and leprologyLipoprotein(a) and livedoid vasculopathy: A new thrombophilic factor?
Medical hypothesesExpanding the spectrum of livedoid vasculopathy: peculiar neuromuscular manifestations.
Neuropathology and applied neurobiologyPulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy: seven cases and a literature review.
Dermatologic therapyLivedoid vasculopathy and high levels of lipoprotein (a): response to danazol.
Dermatologic therapyMononeuritis multiplex associated with primary livedoid vasculopathy: neuropathological evidence of ischemic nerve damage.
Journal of the neurological sciencesAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Vasculopatia livedoide.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Vasculopatia livedoide
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Treatment outcomes in patients of livedoid vasculopathy following antithrombotic therapy: A retrospective observational study.
- Treatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series.
- Livedoid Vasculopathy: Analysis of Hematological Parameters and Response to Rivaroxaban.
- Treatment of livedoid vasculopathy with sulodexide: A prospective study of 35 cases.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG· 2026· PMID 41482702mais citado
- JAK inhibitors in livedoid vasculopathy associated with thrombophilia and refractory to anticoagulation: report and literature review.
- Refractory Livedoid Vasculopathy Successfully Treated with CHAP Therapy and Punch Grafts: Two Case Reports.
- Assessment of the use of biologic drugs in the treatment of primary antiphospholipid syndrome.
- Differential response to Janus kinase inhibitors in refractory livedoid vasculopathy: Biomarker-guided therapy may improve clinical response.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:542643(Orphanet)
- MONDO:0025514(MONDO)
- GARD:12784(GARD (NIH))
- Busca completa no PubMed(PubMed)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
